Rank

Name

Company

Potential Realizable Value Of Option Grants ($000)

FYE Value Of Exercisable In-The-Money Options ($000)

Shares Of Company's Common Stock Owned By CEO (000)

Percent Of Company Owned By CEO (%)

1

Herbert M. Stein (1)

Organogenesis Inc.

10,578

27,277

1,480

6.0

2

Gordon M. Binder

Amgen Inc.

7,443

59,348

1,514

0.6

3

James R. Tobin (2)

Biogen Inc.

6,699

4,748

542

0.7

4

Cam L. Garner

Dura Pharmaceuticals Inc.

5,886

331

94

0.2

5

Michael J. Brennan (3)

Gene Logic Inc.

5,607

1,108

618

4.2

6

John W. Holaday

EntreMed Inc.

4,268

2,200

1,145

9.1

7

Glenn L. Cooper

Interneuron Pharmaceuticals Inc.**

3,885

3,195

942

2.3

8

Philippe Pouletty

SangStat Medical Corp.

3,258

12,229

637

4.0

9

Ronald L. Goode (4)

Unimed Pharmaceuticals Inc.

1,887

3

84

0.9

10

Jeremy M. Levin (5)

Cadus Pharmaceutical Corp

1,861

1,425

290

2.3

NOTES:

* Unless otherwise noted, all compensation data reported are for the fiscal year ending Dec. 31, 1997. This ranking was compiled from a database containing detailed executive compensation data drawn from the proxy statements of 223 public biotechnology companies. "Non-cash compensation" as defined here represents the potential future value of stock options granted to CEOs (most option grants vest over a five to 10 year period). As a point of comparison, we have included data on the value of the CEO's exercisable (or fully vested) options at year's end and the CEO's percentage ownership of his company.

** Denotes fiscal year end of 9/30/97.

FYE = Fiscal year end

DEFINITION OF TERMS

POTENTIAL REALIZABLE VALUE OF OPTION GRANTS: Figures taken directly from proxy statements under the heading "Potential Realizable Value At Assumed Annual Rates of Stock Appreciation For Option Term 5%." This calculation is made according to Securities and Exchange Commission rules and assumes that the stock price on the date of grant appreciates at 5 percent, compounded annually, for the entire term of the option and that the option is exercised and sold on the last day of its term at this appreciated stock price. Fluctuations in stock prices make this estimate of future value highly speculative. For that reason we have reported the more-conservative 5 percent appreciation rate rather than the 10 percent appreciation rate, which is also reported in all proxy statements.

FYE VALUE OF EXERCISABLE IN-THE-MONEY OPTIONS: These data are taken directly from the corresponding section in the proxy statements and represent the value of the optionee's fully vested stock options minus the option exercise price on a given company's fiscal year-end. Changes in stock prices directly affect the value of exercisable in-the-money stock options, which are listed with FYE values (i.e., if the company's stock has lost or gained significant value since Dec. 31, 1997, these figures will increase or decrease accordingly).

SHARES OF COMPANY'S COMMON STOCK OWNED BY CEO: These data are taken directly from the proxy statements and do not account or adjust for shares owned by family members, etc., or any other qualifying information contained in footnotes.

1.) In May 1997, Organogenesis Inc.'s board of directors voted to amend an option granted to CEO Herbert M. Stein in 1987. The option (for 585,938 shares at an exercise price per share of $3.84), which was due to expire in May 1997, was extended for an additional five years. The option is fully vested and had a "Grant Date Value" of $6,304,688 on May 7, 1997.

2.) James R. Tobin resigned his posts as CEO and president of Biogen Inc. on Dec. 23, 1998. James L. Vincent, chairman of the board, was elected to fill Tobin's positions as well. Tobin had been CEO of Biogen since February 1997 and president since February 1994, and had served as chief operating officer from February 1994 to February 1997. Vincent , who had been Biogen's CEO from 1985 to February 1997, then went on to assume the title of chairman.

3.) Gene Logic Inc. acquired OncorMed Inc. in September 1998. Michael J. Brennan's share ownership and the shares outstanding are based upon pre-merger figures.

4.) Ronald L. Goode joined Unimed Pharmaceuticals Inc. as president and CEO on Nov. 13, 1997. He resigned those posts on Feb. 8, 1999, at which point Robert E. Dudley was elected to both positions.

5.) Jeremy M. Levin ceased being the president and CEO of Cadus Pharmaceutical Corp. on Jan. 31, 1998.

No Comments